AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35461434 — intervention group
Group type: EXPERIMENTAL
Intervention: COLD (ice-cold water 0-3 °C)
Number of subjects: 14
Study 35461434 — intervention group
Group type: EXPERIMENTAL
Intervention: WARM (warm water 45 °C)
Number of subjects: 14
Study 35461434 — intervention group
Group type: COMPARATOR
Intervention: ROOM (room temperature water 20 °C)
Number of subjects: 14
Study 33141616 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE (oral conjugated equine estrogens)
Number of subjects: 934
Study 33141616 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE+MPA (oral conjugated equine estrogens and medroxyprogesterone acetate)
Number of subjects: 934
Study 33141616 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE
Number of subjects: 934
Study 33141616 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE+MPA
Number of subjects: 934
Study 33141616 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of 4 metabolites (C58:11 triacylglycerol, C54:9 triacylglycerol, C36:1 phosphatidylcholine, sucrose)
Number of subjects: 934
Study 36096775 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV PROTECT intervention
Number of subjects: 0
Study 36096775 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider perspectives regarding intervention feasibility, acceptability, and appropriateness
Number of subjects: 0
Study 34297008 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral hypnotic suggestibility
Number of subjects: 135
Study 34297008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhypnotic suggestibility
Number of subjects: 135
Study 36115667 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment with gentamicin (80 mg), vancomycin (1 g), and cefazolin (1 g) dissolved in 500 mL of isotonic saline.
Number of subjects: 0
Study 36115667 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution of 500 mL isotonic saline.
Number of subjects: 0
Study 36115667 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment with gentamicin, vancomycin, and cefazolin.
Number of subjects: 0
Study 36115667 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution of isotonic saline.
Number of subjects: 0
Study 33452045 — intervention group
Group type: EXPERIMENTAL
Intervention: CSCI-furosemide (average daily dose 125 mg, duration 10 days)
Number of subjects: 116
Study 33452045 — intervention group
Group type: EXPERIMENTAL
Intervention: CSCI-furosemide
Number of subjects: 116
Study 35791582 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase plus tirofiban
Number of subjects: 96
Study 35791582 — intervention group
Group type: COMPARATOR
Intervention: Urokinase
Number of subjects: 96
Study 32647367 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g whole flaxseed powder
Number of subjects: 100
Study 32647367 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g hesperidin supplementation
Number of subjects: 100
Study 32647367 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g flaxseed and 1 g hesperidin (flax‐hes)
Number of subjects: 100
Study 32647367 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification program (control)
Number of subjects: 100
Study 34081648 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation training provided by a low vision therapist
Number of subjects: 57
Study 34081648 — intervention group
Group type: COMPARATOR
Intervention: Self-training standard offered by the device manufacturer (control group)
Number of subjects: 57
Study 34081648 — intervention group
Group type: EXPERIMENTAL
Intervention: Both telerehabilitation and self-training
Number of subjects: 57
Study 32524803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation combined with therapeutic education
Number of subjects: 80
Study 32524803 — intervention group
Group type: COMPARATOR
Intervention: Cognitive remediation
Number of subjects: 80
Study 36066459 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (early PMS remission)
Number of subjects: 257
Study 36066459 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (early PMS remission)
Number of subjects: 257
Study 33941170 — intervention group
Group type: EXPERIMENTAL
Intervention: Laypeople using a manual toothbrush
Number of subjects: 39
Study 33941170 — intervention group
Group type: EXPERIMENTAL
Intervention: Laypeople using a powered toothbrush
Number of subjects: 39
Study 33941170 — intervention group
Group type: COMPARATOR
Intervention: Dental professionals using a manual toothbrush
Number of subjects: 39
Study 33941170 — intervention group
Group type: COMPARATOR
Intervention: Dental professionals using a powered toothbrush
Number of subjects: 39
Study 33941170 — intervention group
Group type: EXPERIMENTAL
Intervention: Laypeople (all groups)
Number of subjects: 39
Study 33941170 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush (all groups)
Number of subjects: 39
Study 32000176 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Skills Intervention Program
Number of subjects: 12
Study 32000176 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 12
Study 33047116 — intervention group
Group type: EXPERIMENTAL
Intervention: OPG knockdown in HESCs
Number of subjects: 31
Study 33047116 — intervention group
Group type: COMPARATOR
Intervention: Inhibition of Akt activation
Number of subjects: 31
Study 33047116 — intervention group
Group type: COMPARATOR
Intervention: Syndecan-1 knockdown
Number of subjects: 31
Study 33047116 — intervention group
Group type: COMPARATOR
Intervention: Comparison of OPG and Syndecan-1 expression
Number of subjects: 31
Study 34246238 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional disability measured by the PROMIS® Physical Function Short Form‐20 T-score
Number of subjects: 211
Study 34246238 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional disabilities in instrumental activities of daily living, self-care activities, and functional mobility
Number of subjects: 211
Study 34246238 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of musculoskeletal conditions of high impact in functional disability
Number of subjects: 211
Study 32389587 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV detection using real-time PCR and other confirmatory methods
Number of subjects: 62
Study 32389587 — intervention group
Group type: COMPARATOR
Intervention: Positive controls for HPV detection
Number of subjects: 62
Study 32389587 — intervention group
Group type: COMPARATOR
Intervention: Negative controls for HPV detection
Number of subjects: 62
Study 33491619 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended first aid practices
Number of subjects: 357
Study 33491619 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially harmful practices
Number of subjects: 357
Study 33491619 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting only recommended practices
Number of subjects: 357
Study 33491619 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting only potentially harmful practices
Number of subjects: 357
Study 36418143 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing alongside edutainment comics
Number of subjects: 120
Study 36418143 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing alone
Number of subjects: 120
Study 36418143 — intervention group
Group type: EXPERIMENTAL
Intervention: Edutainment comic alone
Number of subjects: 120
Study 36418143 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 120
Study 36418143 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 120
Study 32401106 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic abdominal binder
Number of subjects: 180
Study 32401106 — intervention group
Group type: COMPARATOR
Intervention: Control (no abdominal binder)
Number of subjects: 180
Study 35508053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonothrombolysis and primary coronary angioplasty
Number of subjects: 100
Study 35508053 — intervention group
Group type: COMPARATOR
Intervention: Primary coronary angioplasty
Number of subjects: 100
Study 32991429 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF-based induction chemotherapy (IC) regimen
Number of subjects: 206
Study 32991429 — intervention group
Group type: EXPERIMENTAL
Intervention: TP-based induction chemotherapy (IC) regimen
Number of subjects: 206
Study 32991429 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-based induction chemotherapy (IC) regimen
Number of subjects: 206
Study 33179847 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Number of subjects: 80
Study 33179847 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 33999765 — intervention group
Group type: EXPERIMENTAL
Intervention: Parous women
Number of subjects: 5412
Study 33999765 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of childbirths
Number of subjects: 5412
Study 33999765 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher age at first birth
Number of subjects: 5412
Study 33999765 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at first or last birth
Number of subjects: 5412
Study 33355063 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT focused on perfectionism (CBT‐P)
Number of subjects: 75
Study 33355063 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified protocol for the transdiagnostic treatment of emotional disorders (UP)
Number of subjects: 75
Study 33355063 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 75
Study 36425571 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg Nigella sativa (450 mg soft gelatin capsules twice daily for two weeks)
Number of subjects: 120
Study 36425571 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 IU of vitamin D3 (1000-IU tablets, two tablets once daily)
Number of subjects: 120
Study 36425571 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg Nigella sativa and 2,000 IU of vitamin D3 (same dosing as previous groups)
Number of subjects: 120
Study 36425571 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Nigella sativa and vitamin D3
Number of subjects: 120
Study 36425571 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 120
Study 34362779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary guidance group
Number of subjects: 60
Study 34362779 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted diet group
Number of subjects: 60
Study 34362779 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal diet)
Number of subjects: 60
Study 33217726 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cold-water immersion (cooling) after training sessions for 10 minutes.
Number of subjects: 11
Study 33217726 — intervention group
Group type: COMPARATOR
Intervention: Passive sitting (control) after training sessions for 10 minutes.
Number of subjects: 11
Study 33129356 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified protocol for the transdiagnostic treatment of emotional disorders (n = 35)
Number of subjects: 70
Study 35279873 — intervention group
Group type: EXPERIMENTAL
Intervention: GTCs 540 mg plus vitamin C 50 mg
Number of subjects: 50
Study 35279873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 35279873 — intervention group
Group type: EXPERIMENTAL
Intervention: UVR-exposed skin
Number of subjects: 50
Study 35279873 — intervention group
Group type: EXPERIMENTAL
Intervention: Unexposed skin
Number of subjects: 50
Study 32660488 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal Minimally Invasive Surgery (TAMIS)
Number of subjects: 198
Study 32660488 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic Submucosal Dissection (ESD)
Number of subjects: 198
Study 32660488 — intervention group
Group type: EXPERIMENTAL
Intervention: TAMIS and ESD
Number of subjects: 198
Study 35914929 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PGZ)
Number of subjects: 80
Study 35914929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 33249003 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor/ivacaftor (LUM/IVA)
Number of subjects: 20
Study 33249003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32878963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceralasertib + olaparib
Number of subjects: 192
Study 32878963 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib monotherapy
Number of subjects: 192
Study 32878963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 35704329 — intervention group
Group type: EXPERIMENTAL
Intervention: Licaminlimab (60 mg/mL, 8 drops/day for 15 days, 4 drops/day for 7 days, then matching vehicle for 7 days)
Number of subjects: 43
Study 35704329 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone eye drops (8 drops/day for 15 days, tapering to 1 drop/day over 14 days)
Number of subjects: 43
Study 33432839 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 154
Study 33432839 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 154
Study 33432839 — intervention group
Group type: COMPARATOR
Intervention: β‐blockers
Number of subjects: 154
Study 33432839 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 154
Study 35731535 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 240
Study 35731535 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)
Number of subjects: 240
Study 33035599 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 96
Study 33035599 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 96
Study 33035599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 35871917 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (100 g daily for 6 weeks)
Number of subjects: 66
Study 35871917 — intervention group
Group type: COMPARATOR
Intervention: Ordinary yogurt (100 g daily for 6 weeks)
Number of subjects: 66
Study 32918323 — intervention group
Group type: EXPERIMENTAL
Intervention: zolpidem extended-release (ER)
Number of subjects: 103
Study 32918323 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 103
Study 32711599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanosilver nasal spray post-surgery
Number of subjects: 112
Study 35013710 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r) plus hydroxychloroquine
Number of subjects: 108
Study 35013710 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) plus hydroxychloroquine
Number of subjects: 108
Study 35013710 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ATV/r and LPV/r
Number of subjects: 108
Study 33139173 — intervention group
Group type: EXPERIMENTAL
Intervention: Throat pack
Number of subjects: 54
Study 33139173 — intervention group
Group type: COMPARATOR
Intervention: Without throat pack
Number of subjects: 54
Study 32725352 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% bupivacaine infusion via mcTAP catheters
Number of subjects: 52
Study 32725352 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion via mcTAP catheters (Control)
Number of subjects: 52
Study 33481452 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia injection followed by ULB in the right eyelid and then in the left (Group A)
Number of subjects: 40
Study 33481452 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia injection to both eyelids followed by ULB on both eyelids (Group B)
Number of subjects: 40
Study 33481452 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 40
Study 32358782 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV biofeedback (HRVB) training, 4-6 weekly sessions until skill acquisition
Number of subjects: 34
Study 32358782 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV biofeedback (HRVB) training
Number of subjects: 34
Study 32358782 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 34
Study 33021579 — intervention group
Group type: COMPARATOR
Intervention: Traditional Sets (TS; 4 sets of 10 with 95 seconds of interset rest)
Number of subjects: 11
Study 33021579 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest-Redistribution (RR; 20 sets of 2 with 15 seconds of interset rest)
Number of subjects: 11
Study 34148297 — intervention group
Group type: EXPERIMENTAL
Intervention: Test cefradine capsules (250 mg single dose) under fasting conditions
Number of subjects: 0
Study 34148297 — intervention group
Group type: COMPARATOR
Intervention: Reference cefradine capsules (250 mg single dose) under fasting conditions
Number of subjects: 0
Study 34148297 — intervention group
Group type: EXPERIMENTAL
Intervention: Test cefradine capsules (250 mg single dose) under fed conditions
Number of subjects: 0
Study 34148297 — intervention group
Group type: COMPARATOR
Intervention: Reference cefradine capsules (250 mg single dose) under fed conditions
Number of subjects: 0
Study 32054486 — intervention group
Group type: EXPERIMENTAL
Intervention: TFD containing 140 mg of caffeine
Number of subjects: 32
Study 32054486 — intervention group
Group type: EXPERIMENTAL
Intervention: TFD containing 100 mg of caffeine
Number of subjects: 32
Study 32054486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 34757657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensartinib (225 mg) after a high-fat, high-calorie meal
Number of subjects: 24
Study 33309784 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 80
Study 33309784 — intervention group
Group type: COMPARATOR
Intervention: Placebo-TENS
Number of subjects: 80
Study 36206054 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) protocol consisting of four cycles of 5 min of leg ischemia
Number of subjects: 36
Study 36206054 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 36
Study 32826409 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal-administered NICU-based bundle of interventions
Number of subjects: 11
Study 36416882 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based out-of-hospital neonatal jaundice screening app
Number of subjects: 1424
Study 36416882 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 1424
Study 32758684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji IX Gold Label (GC Corp)
Number of subjects: 150
Study 32758684 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitro Molar (nova DFL)
Number of subjects: 150
Study 32758684 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxxion R (FGM)
Number of subjects: 150
Study 32758684 — intervention group
Group type: COMPARATOR
Intervention: Low-cost glass ionomers (Vitro Molar and Maxxion R)
Number of subjects: 150
Study 36253284 — intervention group
Group type: EXPERIMENTAL
Intervention: SUGAR intervention with usual care
Number of subjects: 212
Study 36253284 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 212
Study 33413104 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with 15 ml (0.25%) ropivacaine on each side
Number of subjects: 159
Study 33413104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no TAP block)
Number of subjects: 159
Study 32574722 — intervention group
Group type: EXPERIMENTAL
Intervention: abiraterone + prednisone
Number of subjects: 547
Study 32574722 — intervention group
Group type: EXPERIMENTAL
Intervention: enzalutamide
Number of subjects: 547
Study 32574722 — intervention group
Group type: COMPARATOR
Intervention: abiraterone or enzalutamide
Number of subjects: 547
Study 34758731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate hydrate (FC)
Number of subjects: 93
Study 34758731 — intervention group
Group type: COMPARATOR
Intervention: Control (non-iron-based phosphate binder)
Number of subjects: 93
Study 34942136 — intervention group
Group type: EXPERIMENTAL
Intervention: Risdiplam (5.00 mg for individuals ≥20 kg or 0.25 mg/kg for individuals <20 kg)
Number of subjects: 180
Study 34942136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 34942136 — intervention group
Group type: EXPERIMENTAL
Intervention: Risdiplam
Number of subjects: 180
Study 32094459 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5 (10 µg/m3 increase in 3-day moving average, lag 0-2)
Number of subjects: 0
Study 32094459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (20 ppb increase in 3-day moving average, lag 0-2)
Number of subjects: 0
Study 37365436 — intervention group
Group type: EXPERIMENTAL
Intervention: Relugolix plus E2 1 mg and NETA 0.5 mg
Number of subjects: 48
Study 37365436 — intervention group
Group type: COMPARATOR
Intervention: Relugolix 40 mg alone
Number of subjects: 48
Study 34410234 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic spine manipulation along with conventional physical therapy
Number of subjects: 60
Study 34410234 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 60
Study 34757340 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided multiple nerve blocks (fascia iliaca compartment block+sacral plexus block+superior cluneal nerve block)
Number of subjects: 94
Study 34757340 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 94
Study 34757340 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided multiple nerve blocks
Number of subjects: 94
Study 32824394 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) treatment group
Number of subjects: 44
Study 32824394 — intervention group
Group type: COMPARATOR
Intervention: Exercise treatment group
Number of subjects: 44
Study 34913256 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative attitude to treatment
Number of subjects: 142
Study 34913256 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived recovery
Number of subjects: 142
Study 34913256 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 142
Study 34913256 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention
Number of subjects: 142
Study 35025593 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate practice (DP) training
Number of subjects: 109
Study 35025593 — intervention group
Group type: COMPARATOR
Intervention: Control group (consultation training as usual)
Number of subjects: 109